11. Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study. Issue 4 (May 2017) Authors: Trottier, Benoît; Lake, Jordan E; Logue, Ken; Brinson, Cynthia; Santiago, Lizette; Brennan, Clare; Koteff, Justin A; Wynne, Brian; Hopking, Judy; Granier, Catherine; Aboud, Michael Journal: Antiviral therapy Issue: Volume 22:Issue 4(2017) Page Start: 295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Dolutegravir/rilpivirine 2-drug regimen comparable to commonly prescribed 3-drug regimens up to 18-months in a real-world setting. Issue 1 (20th January 2022) Authors: Pierone, Gerald; Fusco, Jennifer S; Vannappagari, Vani; Brunet, Laurence; Weber, Rachel P; Aboud, Michael; van Wyk, Jean; Ragone, Leigh; Fusco, Gregory P Journal: Antiviral therapy Issue: Volume 27:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. (1st March 2020) Authors: Cahn, Pedro; Madero, Juan Sierra; Arribas, José R.; Antinori, Andrea; Ortiz, Roberto; Clarke, Amanda E.; Hung, Chien-Ching; Rockstroh, Jürgen K.; Girard, Pierre-Marie; Sievers, Jörg; Man, Choy Y.; Urbaityte, Rimgaile; Brandon, Daisy J.; Underwood, Mark; Tenorio, Allan R.; Pappa, Keith A.; Wynne, ... Journal: Journal of acquired immune deficiency syndromes Issue: Volume 83:Number 3(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Issue 9 (September 2019) Authors: Aboud, Michael; Orkin, Chloe; Podzamczer, Daniel; Bogner, Johannes R; Baker, David; Khuong-Josses, Marie-Aude; Parks, David; Angelis, Konstantinos; Kahl, Lesley P; Blair, Elizabeth A; Adkison, Kimberly; Underwood, Mark; Matthews, Jessica E; Wynne, Brian; Vandermeulen, Kati; Gartland, Martin; Smit... Journal: Lancet Issue: Volume 6:Issue 9(2019) Page Start: e576 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. (6th January 2020) Authors: van Wyk, Jean; Ajana, Faïza; Bisshop, Fiona; De Wit, Stéphane; Osiyemi, Olayemi; Portilla Sogorb, Joaquín; Routy, Jean-Pierre; Wyen, Christoph; Ait-Khaled, Mounir; Nascimento, Maria Claudia; Pappa, Keith A; Wang, Ruolan; Wright, Jonathan; Tenorio, Allan R; Wynne, Brian; Aboud, Michael; Gartland, ... Journal: Clinical infectious diseases Issue: Volume 71:Number 8(2020) Page Start: 1920 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial . (25th January 2022) Authors: Osiyemi, Olayemi; De Wit, Stéphane; Ajana, Faïza; Bisshop, Fiona; Portilla, Joaquín; Routy, Jean Pierre; Wyen, Christoph; Ait-Khaled, Mounir; Leone, Peter; Pappa, Keith A; Wang, Ruolan; Wright, Jonathan; George, Nisha; Wynne, Brian; Aboud, Michael; van Wyk, Jean; Smith, Kimberly Y Journal: Clinical infectious diseases Issue: Volume 75:Number 6(2022) Page Start: 975 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study. Issue 2 (22nd April 2022) Authors: Brown, Dannae; Kaplan, Richard; Losso, Marcelo; Brites, Carlos; Wang, Ruolan; Underwood, Mark; Hopking, Judy; Aboud, Michael; Sievers, Jörg Journal: Antiviral therapy Issue: Volume 27:Issue 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study. Issue 1 (13th January 2022) Authors: Brown, Dannae; Kaplan, Richard; Losso, Marcelo; Brites, Carlos; Wang, Ruolan; Underwood, Mark; Hopking, Judy; Aboud, Michael; Sievers, Jörg Journal: Antiviral therapy Issue: Volume 27:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Issue 10123 (3rd March 2018) Authors: Llibre, Josep M; Hung, Chien-Ching; Brinson, Cynthia; Castelli, Francesco; Girard, Pierre-Marie; Kahl, Lesley P; Blair, Elizabeth A; Angelis, Kostas; Wynne, Brian; Vandermeulen, Kati; Underwood, Mark; Smith, Kim; Gartland, Martin; Aboud, Michael Journal: Lancet Issue: Volume 391:Issue 10123(2018) Page Start: 839 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. (15th July 2021) Authors: Cutrell, Amy G.; Schapiro, Jonathan M.; Perno, Carlo F.; Kuritzkes, Daniel R.; Quercia, Romina; Patel, Parul; Polli, Joseph W.; Dorey, David; Wang, Yongwei; Wu, Sterling; Van Eygen, Veerle; Crauwels, Herta; Ford, Susan L.; Baker, Mark; Talarico, Christine L.; Clair, Marty St; Jeffrey, Jerry; Whit... Journal: AIDS Issue: Volume 35:Number 9(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗